Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT Clinical Trial

Official title: Cytomegalovirus (CMV) Reactivation in Post-allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) Patients: Salvage and Prophylactic Treatments of Nilotinib

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether nilotinib is effective in the prophylaxis and treatment of CMV reactivation in allo-HSCT patients.

Clinical Trial Description

The purpose of this study is to determine whether nilotinib is effective in the prophylaxis and treatment of CMV reactivation in allo-HSCT patients.

Prophylaxis Part: patients will be treated with nilotinib after their hemogram engraftment to prevent CMV reactivation Salvage Part: patients who have had intractable CMV reactivation after gancyclovir therapy will be treated with nilotinib ;

Related Conditions & MeSH terms

• Patients Who Have Received Allo-HSCT

• NCT number: NCT01252017
• Study type: Interventional
• Source: National Taiwan University Hospital
• Status: Completed
• Phase: Phase 2
• Start date: November 2010
• Completion date: November 2014